Published in Am J Physiol on May 01, 1993
Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest (1999) 2.09
Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol (2003) 1.34
Prenatal gender-related nicotine exposure increases blood pressure response to angiotensin II in adult offspring. Hypertension (2008) 1.28
Prenatal programming of angiotensin II type 2 receptor expression in the rat. Br J Nutr (2004) 1.28
Sex-specific effects of prenatal low-protein and carbenoxolone exposure on renal angiotensin receptor expression in rats. Hypertension (2005) 1.22
Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol (1994) 1.01
Angiotensin II type-2 receptor-specific effects on the cardiovascular system. Cardiovasc Diagn Ther (2012) 0.94
The role of bradykinin, AT2 and angiotensin 1-7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat. Br J Pharmacol (2004) 0.84
Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Br J Pharmacol (1995) 0.82
Role of ACE/AT2R complex in the control of mesenteric resistance artery contraction induced by ACE/AT1R complex activation in response to Ang I. Mol Cell Biochem (2007) 0.80
Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries. Br J Pharmacol (1999) 0.77
The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice. J Clin Invest (1999) 0.76
Attenuation of ligand-induced activation of angiotensin II type 1 receptor signaling by the type 2 receptor via protein kinase C. Sci Rep (2016) 0.76
The acute vascular effects of frusemide in heart failure. Br J Clin Pharmacol (2000) 0.76
Angiotensin II during Experimentally Simulated Central Hypovolemia. Front Cardiovasc Med (2016) 0.75
Evidence for L-glutamate as the neurotransmitter of baroreceptor afferent nerve fibers. Science (1980) 1.29
Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res (1992) 1.28
Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol (1988) 1.25
Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol (1991) 1.20
Demonstration of vasorelaxant activity with an A1-selective adenosine agonist in porcine coronary artery: involvement of potassium channels. J Pharmacol Exp Ther (1992) 1.17
RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther (1997) 1.03
Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther (1998) 1.00
Acute hypertension after the local injection of kainic acid into the nucleus tractus solitarii of rats. Circ Res (1981) 0.91
Inhibition of EGF-induced vasoconstriction in isolated rabbit aortic rings with the tyrosine kinase inhibitor RG50864. Biochem Biophys Res Commun (1993) 0.90
Regulation of pituitary receptors for thyrotropin-releasing hormone by thyroid hormones. J Biol Chem (1978) 0.89
Evidence that glutamic acid is the neurotransmitter of baroreceptor afferent terminating in the nucleus tractus solitarius (NTS). J Auton Nerv Syst (1981) 0.88
Pharmacological analysis of alpha-2 adrenergic mechanisms in nociception and ataxia. J Pharmacol Exp Ther (1985) 0.88
Biochemical evidence that L-glutamate is a neurotransmitter of primary vagal afferent nerve fibers. Brain Res (1981) 0.86
In vitro and in vivo characterization of an A1-selective adenosine agonist, RG14202. J Pharmacol Exp Ther (1993) 0.84
Cardiovascular and metabolic effects of adenosine A1-receptor agonists in streptozotocin-treated rats. J Cardiovasc Pharmacol (1997) 0.84
Estimation of the in vivo effect of cyclooxygenase inhibitors on prostaglandin E2 levels in mouse brain. Eur J Pharmacol (1990) 0.84
Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther (1989) 0.83
Relationships between thyroid hormone and glucocorticoid effects in GH3 pituitary cells. Endocrinology (1980) 0.83
Phorbol-12,13-dibutyrate-induced vasoconstriction in vivo: characterization of response in genetic hypertension. J Pharmacol Exp Ther (1990) 0.83
Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: coronary hemodynamic and cardioprotective effects in the canine myocardium. J Cardiovasc Pharmacol (1999) 0.82
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines. J Med Chem (1987) 0.82
In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor. Eur J Pharmacol (1992) 0.82
Differential alteration of vascular reactivity in rabbit aorta with modest elevation of serum cholesterol. Circ Res (1990) 0.81
Identification and characterization of substance P receptors on LRM55 glial cells. J Pharmacol Exp Ther (1986) 0.81
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery. Thromb Haemost (1997) 0.81
Binding of [3H]substance P to putative substance P receptors in rat brain membranes. Eur J Pharmacol (1983) 0.80
1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittelforschung (1996) 0.80
Antagonism of the baroreceptor reflex by glutamate diethyl ester, an antagonist to L-glutamate. Brain Res (1981) 0.80
Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. Arterioscler Thromb Vasc Biol (1998) 0.79
Thyroid hormone action in pituitary cells. Differences in the regulation of thyrotropin-releasing hormone receptors and growth hormone synthesis. J Biol Chem (1979) 0.79
Mechanism of thyroid hormone inhibition of thyrotropin-releasing hormone action. Endocrinology (1981) 0.79
RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.79
Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs. Thromb Res (2001) 0.79
Protein kinase C and vascular smooth muscle contractility: effects of inhibitors and down-regulation. J Pharmacol Exp Ther (1991) 0.79
Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa. J Med Chem (1998) 0.78
Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats. J Cardiovasc Pharmacol (1997) 0.78
Characterization and inhibition of 15-lipoxygenase in human monocytes: comparison with soybean 15-lipoxygenase. Am J Physiol (1995) 0.78
Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa. J Cardiovasc Pharmacol (1999) 0.78
Angiotensin subtype 1 blockade selectively potentiates adenosine subtype 2-mediated vasodilation. Hypertension (1993) 0.77
In vitro characterization of a novel factor Xa inhibitor, RPR 130737. Thromb Res (2000) 0.77
Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br J Pharmacol (2001) 0.77
Electrode cuff-induced changes in DNA and PDGF gene expression in the rat carotid artery. Atherosclerosis (1993) 0.77
Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem (1999) 0.76
Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res (2001) 0.76
Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. Pharmacology (1995) 0.76
Ischaemia/reperfusion selectively attenuates coronary vasodilatation to an adenosine A2- but not to an A1-agonist in the dog. Br J Pharmacol (1994) 0.75
Does tumor necrosis factor-alpha (TNF-alpha) contribute to myocardial reperfusion injury in anesthetized rats? Gen Pharmacol (1999) 0.75
The role of the neutrophil and formed elements of the blood in an in vitro model of reperfusion injury. Mediators Inflamm (1993) 0.75
RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit. Thromb Haemost (1999) 0.75
Lovastatin is hypertriglyceridemic in Syrian golden hamsters. Biochem Biophys Res Commun (1988) 0.75
Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist. Thromb Res (1996) 0.75
RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Pharmacology (1993) 0.75
Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs. J Cardiovasc Pharmacol (2001) 0.75
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives. J Med Chem (1987) 0.75
Pharmacology of RG W-2938: a cardiotonic agent with vasodilator activity. J Cardiovasc Pharmacol (1990) 0.75